Logo

No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine

1, 2, 3, 4, 5, 6

  1. Paediatric Cardiology, New York Medical College, USA.
  2. Paediatric Cardiology, Children’s and Women’s Physicians of Westchester LLP, Norwalk, CT, USA.
  3. Pathology, Johns Hopkins Medicine, Baltimore, MD, USA.
  4. Medicine, Division of Rheumatology, New York University School of Medicine, New York, USA.
  5. Medicine, Division of Rheumatology, New York University School of Medicine, New York, USA.
  6. Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, USA. jill.buyon@nyumc.org

CER10192 Submission on line
2017 Vol.35, N°5 - PI 0857, PF 0859
Case Report

Rheumatology Article

 

Abstract

It is currently recommended that hydroxychloroquine (HCQ) be maintained during pregnancy in patients with systemic lupus erythematosus. Recent data suggest that this Toll-like receptor inhibitor may also reduce the recurrence rate of anti-SSA/Ro associated congenital heart block (CHB). This case report describes a unique situation in which a CHB-afflicted, HCQ-exposed pregnancy was electively terminated. The heart did not reveal any characteristic features of cardiotoxicity, providing further evidence supporting the safety of foetal exposure to HCQ.

PMID: 28598777 [PubMed]

Received: 19/12/2016 - Accepted : 28/03/2017 - In Press: 06/06/2017 - Published: 15/09/2017